World's 1st iPS clinical research to begin

World's 1st iPS clinical research to begin

KOBE, Japan - Masayo Takahashi, project leader from the state-backed scientific research institute Riken, speaks at a news conference in Kobe, Hyogo Prefecture, on July 30, 2013. Riken and the Foundation for Biomedical Research and Innovation said that the world's first clinical research using induced pluripotent stem cells, known as iPS cells, for the regeneration of retina will begin on August 1, 2013.

  • Product Code
  • ILEA001185380
  • Registered date
  • 2013/7/30 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2013 Kyodo News
  • Media size
  • 3968 × 2628 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 675.26(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Retina transplants via donor iPS cells

    Retina transplants via donor iPS cells

    Masayo Takahashi, a researcher at the Japanese government-backed Riken institute, speaks at an academic conference in Tokyo on April 18, 2019. Five patients suffering a severe eye disease were doing well a year after they received in 2017 the world's first transplant surgeries using induced pluripotent stem cells from donors, she said. (Kyodo) ==Kyodo
      Retina transplants via donor iPS cells

      Retina transplants via donor iPS cells

      Photo taken Nov. 10, 2017, shows Masayo Takahashi, a researcher at the Japanese government-backed Riken institute. She said in Tokyo on April 18, 2019 that five patients suffering a severe eye disease were doing well a year after they received in 2017 the world's first transplant surgeries using induced pluripotent stem cells from donors. (Kyodo) ==Kyodo
        Purported "STAP cells" likely came from embryonic stem cells

        Purported "STAP cells" likely came from embryonic stem cells

        TOKYO, Japan - Isao Katsura, director general of the National Institute of Genetics and leader of a panel under the Riken research institute, attends a press conference in Tokyo on Dec. 26, 2014, to announce that the "STAP cells" that scientist Haruko Obokata, who left Riken on Dec. 21, claimed to have created were likely cells generated from embryonic stem cells.
          Purported "STAP cells" likely came from embryonic stem cells

          Purported "STAP cells" likely came from embryonic stem cells

          TOKYO, Japan - Isao Katsura (far R), director general of the National Institute of Genetics and leader of a panel under the Riken research institute, attends a press conference along with other panel members in Tokyo on Dec. 26, 2014, to announce that the "STAP cells" that scientist Haruko Obokata, who left Riken on Dec. 21, claimed to have created were likely cells generated from embryonic stem cells.
            Purported "STAP cells" likely came from embryonic stem cells

            Purported "STAP cells" likely came from embryonic stem cells

            TOKYO, Japan - Isao Katsura (L), director general of the National Institute of Genetics and leader of a panel under the Riken research institute, attends a press conference along with other panel members in Tokyo on Dec. 26, 2014, to announce that the "STAP cells" that scientist Haruko Obokata, who left Riken on Dec. 21, claimed to have created were likely cells generated from embryonic stem cells.
              World's 1st transplant surgery using iPS cells conducted

              World's 1st transplant surgery using iPS cells conducted

              KOBE, Japan - Masayo Takahashi, researcher of the Riken Center for Developmental Biology, smiles during a press conference in Kobe, western Japan, on Sept. 12, 2014, after a Japanese research team led by Takahashi transplanted retinal cells grown from induced pluripotent stem cells to a woman in her 70s. It marked the first time iPS-derived cells have been introduced into a human body by surgery.
                World's 1st transplant surgery using iPS cells conducted

                World's 1st transplant surgery using iPS cells conducted

                KOBE, Japan - Masayo Takahashi, researcher of the Riken Center for Developmental Biology, holds a press conference in Kobe, western Japan, on Sept. 12, 2014, after a Japanese research team led by Takahashi transplanted retinal cells grown from induced pluripotent stem cells to a woman in her 70s. It marked the first time iPS-derived cells have been introduced into a human body by surgery.
                  World's 1st transplant surgery using iPS cells conducted

                  World's 1st transplant surgery using iPS cells conducted

                  KYOTO, Japan - Kyoto University professor Shinya Yamanaka holds a press conference in Kyoto on Sept. 12, 2014, after a Japanese research team transplanted retinal cells grown from induced pluripotent stem cells to a woman in her 70s earlier in the day, marking the first time iPS-derived cells have been introduced into a human body by surgery. Yamanaka developed iPS cells, a type of stem cells that can grow into various human body tissue.
                    World's 1st transplant surgery using iPS cells conducted

                    World's 1st transplant surgery using iPS cells conducted

                    KOBE, Japan - Masayo Takahashi, researcher of the Riken Center for Developmental Biology, holds a press conference in Kobe, western Japan, on Sept. 12, 2014, after a Japanese research team led by Takahashi transplanted retinal cells grown from induced pluripotent stem cells to a woman in her 70s. It marked the first time iPS-derived cells have been introduced into a human body by surgery. (Kyodo)
                      World's 1st iPS cell transplant

                      World's 1st iPS cell transplant

                      OSAKA, Japan - Masayo Takahashi (L), project leader at Riken Center for Developmental Biology, inspects an experiment at Riken's stem cell culture laboratory in Kobe, western Japan, in February 2013. A Japanese team has recently conducted the world's first surgery to implant tissue derived from induced pluripotent stem cells into a human body as part of the clinical study led by Takahashi and others.